ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί

Código QR

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί

(1) Background: Mutations in epidermal growth factor receptor (EGFR) proteins account for many non-small cell lung cancers (NSCLCs), and EGFR tyrosine kinase inhibitors (TKIs) are being used as targeted therapeutics. However, resistance to TKIs continues to increase owing to additional mutations in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeon-Soo Lee, Young Eun Choi, Sunshin Kim, Ji-Youn Han, Sung-Ho Goh
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ELF3 non-small cell lung cancer EGFR EGFR-TKI resistance PKCί auranofin Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/efd73dcc6d8f45e9ab8e60d396186314
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Yurong Wang, et al.
Publicado: (2021)

Loss of FBP1 by aPKC-ι/Snail Pathway-Mediated Repression Promotes Invasion and Aerobic Glycolysis of Intrahepatic Cholangiocarcinoma
por: Meng Gao, et al.
Publicado: (2021)

Identification of lncRNA–miRNA–mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor
por: Ting Wang, et al.
Publicado: (2021)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà T
Publicado: (2017)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang SS, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Taichi Miyawaki, et al.
Publicado: (2021)

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
por: Kim JS, et al.
Publicado: (2018)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to Therapy
por: Fan Chen, et al.
Publicado: (2021)

Expression of PKCι/YAP1 in Cervical Cancer and Its Clinical Significance
por: CHEN Shengmin, et al.
Publicado: (2021)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Elli Narvi, et al.
Publicado: (2018)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
por: Xuan Zhou, et al.
Publicado: (2021)

Inhibition of EGFR Signaling Protects from Mucormycosis
por: Tonya N. Watkins, et al.
Publicado: (2018)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
por: Mohammed A. S. Abourehab, et al.
Publicado: (2021)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu D, et al.
Publicado: (2021)

eGFRs from Asian-modified CKD-EPI and Chinese-modified CKD-EPI equations were associated better with hypertensive target organ damage in the community-dwelling elderly Chinese: the Northern Shanghai Study
por: Ji H, et al.
Publicado: (2017)

Theatre City and Identity: Narodno pozorište-Nepszίnház-KPGT
por: Lazar Jovanov
Publicado: (2016)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
por: YingYing He, et al.
Publicado: (2021)

Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
por: Kunyan He, et al.
Publicado: (2021)

Canine parvovirus induces G1/S cell cycle arrest that involves EGFR Tyr1086 phosphorylation
por: Xiaofeng Dai, et al.
Publicado: (2020)

FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma
por: Mariana Cooke, et al.
Publicado: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Lamellipodin-RICTOR Signaling Mediates Glioblastoma Cell Invasion and Radiosensitivity Downstream of EGFR
por: Stefanie Moritz, et al.
Publicado: (2021)

Comparison of Proliferative Activity of Epithelial Cells between the Follicles of Impacted Teeth
por: Kömerik,Nurgül, et al.
Publicado: (2014)

Aldosterone rapidly activates p-PKC delta and GPR30 but suppresses p-PKC epsilon protein levels in rat kidney
por: Eiam-Ong Somchit, et al.
Publicado: (2019)

SIGNIFICANCE OF RENAL FUNCTION IN TRAUMA: AN OBSERVATIONAL STUDY TO ASCERTAIN CORRELATION TO EGFR
por: Syed Faraz Ahmed, et al.
Publicado: (2020)

EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles
por: Tsai WH, et al.
Publicado: (2018)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang WT, et al.
Publicado: (2018)

Design of New Quinazoline Derivative as EGFR (Epidermal Growth Factor Receptor) Inhibitor through Molecular Docking and Dynamics Simulation
por: Herlina Rasyid, et al.
Publicado: (2020)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Haomin Zhang, et al.
Publicado: (2021)

Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer
por: Wu Y, et al.
Publicado: (2020)

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
por: Oh F, et al.
Publicado: (2018)

Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
por: Guangchuan Deng, et al.
Publicado: (2021)

Gold nanoparticles affect the antioxidant status in selected normal human cells
por: Daems N, et al.
Publicado: (2019)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1
por: Ruing Zhao, et al.
Publicado: (2021)